DCTH - Delcath Systems, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Delcath Systems, Inc.

1633 Broadway
22nd Floor Suite C
New York, NY 10019
United States

IndustryMedical Devices
Full Time Employees43

Key Executives

NameTitlePayExercisedYear Born
Dr. Jennifer K. SimpsonPres, CEO & Director541.59kN/A1968
Ms. Barbra C. Keck M.B.A., MBACFO & Sec.374kN/A1978
Mr. John Purpura M.S.Exec. VP & Global Head of Operations385kN/A1961
Mr. Thomas JohnsonSr. Director of Corp. CommunicationsN/AN/AN/A
Mr. Robin WaggeSr. VP of Rubenstein AssociatesN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's investigational products include melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its clinical development program consists of FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial that is in Phase 3 clinical trial for intrahepatic cholangiocarcinoma. It also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.

Corporate Governance

Delcath Systems, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.